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Summary (2 sentences to summarize the work that is used for journal’s facebook 
page) 
An extended analysis of RESONATE-2 demonstrates that first-line treatment with 
ibrutinib provides sustained progression-free survival benefits, with depth of response 
improving over time without unexpected toxicity concerns in older patients with chronic 
lymphocytic leukemia. Additionally, ibrutinib overcomes the adverse prognostic impact 
of del (11q) and unmutated IGHV status.  
 
Trial registration: ClinicalTrials.gov identifiers: NCT01722487 and NCT01724346 
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Abstract (250-word limit; single paragraph only): 250 
Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line 
treatment of chronic lymphocytic leukemia. Extended analysis of RESONATE-2 was 
conducted to determine long-term efficacy and safety of ibrutinib in older patients with 
chronic lymphocytic leukemia. A total of 269 patients aged ≥65 years with previously 
untreated chronic lymphocytic leukemia without del(17p) were randomized 1:1 to 
ibrutinib (n=136) or chlorambucil (n=133) on days 1 and 15 of a 28-day cycle for 12 
cycles. Median ibrutinib treatment duration was 28.5 months. Ibrutinib significantly 
prolonged progression-free survival versus chlorambucil (median, not reached vs 15 
months; hazard ratio, 0.12; 95% confidence interval, 0.07-0.20; P < .0001). The 24-
month progression-free survival was 89% with ibrutinib (97% and 89% in patients with 
del[11q] and unmutated immunoglobulin heavy chain variable region gene, respectively). 
Progression-free survival rates at 24 months were also similar regardless of age (<75 
years [88%], ≥75 years [89%]). Overall response rate was 92% (125/136). Rate of 
complete response increased substantially from 7% at 12 months to 18% with extended 
follow-up. Greater quality of life improvements occurred with ibrutinib versus 
chlorambucil in Functional Assessment of Chronic Illness Therapy-Fatigue (P=.0013). 
The most frequent grade ≥3 adverse events were neutropenia (12%), anemia (7%), and 
hypertension (5%). Rate of discontinuations due to adverse events was 12%. Results 
demonstrated that first-line ibrutinib for elderly patients with chronic lymphocytic 
leukemia provides sustained response and progression-free survival benefits over 
chemotherapy with depth of response improving over time without new toxicity concerns. 
This trial was registered at clinicaltrials.gov (NCT01722487 and NCT01724346).  
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Introduction 
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries 
and is increasing in prevalence with the prolonged survival observed with introduction of 
novel combinations and targeted treatments such as ibrutinib.1 With a median age at 
diagnosis of 71 years,1 management of this predominately older population is 
controversial given that frequent comorbidities often preclude aggressive therapy. 
Randomized studies have provided disparate results in older compared with younger 
patients.2,3 Less intensive approaches, such as chlorambucil, provide limited response 
durability. While the addition of anti-CD20 antibodies has improved outcomes achieved 
with single-agent chlorambucil, administration of these intravenous agents has 
associated toxicity, and response durations remain limited.4 
 
The first-in-class, oral, once-daily, Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib 
targets signaling via the B-cell receptor cascade, critical to survival of malignant 
lymphocytes.5-9 Ibrutinib demonstrated tolerability, a high rate of objective responses, 
and prolongation of progression-free survival and overall survival in patients with 
relapsed/refractory CLL.10 Early-phase studies demonstrated responses of up to 84% in 
previously untreated patients with complete response (CR) rates of up to 23% and up to 
3 years of median follow-up.11,12 This small cohort suggested that single-agent ibrutinib 
might provide durable efficacy in first-line treatment of patients with CLL while avoiding 
toxicity inherent to cytotoxic or other infused regimens.  
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RESONATE-2, was an international phase 3 study designed to definitively evaluate 
first-line ibrutinib treatment in older patients who often had baseline frailties against a 
standard chemotherapeutic agent, chlorambucil.13 Primary results demonstrated an 84% 
reduction in the risk of death at a median follow-up of 18 months for ibrutinib compared 
with chlorambucil. Based on these findings, ibrutinib received approval in the United 
States, Europe, and other regions for the first-line treatment of patients with CLL, and 
allows for treatment without chemotherapy.14,15 A detailed analysis of overall survival 
(OS) with longer follow-up and adjustment for the impact of treatment crossover was 
previously reported.16 A separate data cut was subsequently performed after this 
detailed OS analysis to evaluate additional outcomes after long-term follow-up. Herein, 
we present the extended analysis of additional outcomes from RESONATE-2 including 
quality-of-life (QOL) measures that may help guide appropriate use of ibrutinib for 
previously untreated patients.  
 
Methods 
Study design and population 
Eligible patients for RESONATE-2 (PCYC-1115/1116; NCT01722487/NCT01724346) 
had previously untreated CLL or SLL with active disease and were ≥65 years. Patients 
≤70 years of age must have had a comorbidity that precluded treatment with 
fludarabine-cyclophosphamide-rituximab. Eligible patients had an Eastern Cooperative 
Oncology Group (ECOG) performance status ≤2, absolute neutrophil count ≥1000 
cells/mm3, platelet count ≥50,000/mm3, and adequate liver and kidney function. Those 
with del(17p) CLL were excluded. 
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This study was conducted according to principles of the Declaration of Helsinki and the 
International Conference on Harmonisation Guidelines for Good Clinical Practice and 
approved by the institutional review boards of participating institutions. All patients 
provided written informed consent. 
 
Patients were randomly assigned in a 1:1 ratio to treatment with oral ibrutinib, 420 mg 
once daily until disease progression or chlorambucil, 0.5 mg/kg (increased up to 0.8 
mg/kg based on tolerability) on days 1 and 15 of a 28-day cycle for 12 cycles. Patients 
from the chlorambucil treatment arm with independent review committee (IRC)-
confirmed disease progression were eligible to cross over to second-line treatment with 
ibrutinib at the investigator’s discretion. 
 
End points and assessments 
End points included progression-free survival (PFS, defined as time from randomization 
to progression or death, whichever occurs earlier), overall survival (OS), overall 
response rate (ORR), improvement in hematologic variables, patient-reported health-
related QOL, and safety. Disease progression and response was determined by 
investigator. QOL was assessed using the Functional Assessment of Chronic Illness 
Therapy (FACIT)-Fatigue questionnaires. Safety assessments included adverse events 
(AEs) and laboratory parameters. Nonhematologic AEs were graded using Common 
Terminology Criteria for Adverse Events, v4.03. Hematologic AEs were graded using 
International Workshop on CLL criteria.17 
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Statistical analyses 
PFS and OS were analyzed using Kaplan-Meier estimates and a 2-sided log-rank test 
stratified by the randomization factors. Sensitivity analyses were performed to adjust for 
the impact of crossover on OS as previously described.16 ORR was analyzed with the 
Cochran-Mantel-Haenszel chi-square test, stratified by the randomization factors. QOL 
analyses were based on the proportion of patients with clinically meaningful changes in 
scores from baseline (≥3 points for FACIT-Fatigue). Additional QOL analyses used 
time-dependent mixed-models repeated measures analysis. 
 
Results 
Patients 
There were 269 patients randomly assigned to ibrutinib (n=136) or chlorambucil (n=133) 
monotherapy in the RESONATE-2 study (Figure S1).13 Patient characteristics were well 
balanced across treatment arms, as previously reported (Table 1).13 The median patient 
age was 73 years on the ibrutinib arm and 72 years on the chlorambucil arm. In the 
ibrutinib treatment arm, of those evaluated, 22% (29/130) had del(11q), and 48% 
(58/121) had unmutated IGHV. Patients initiated ibrutinib treatment for active disease 
per iwCLL criteria, most commonly manifesting as marrow failure (progressive anemia 
or thrombocytopenia [40%]), progressive or symptomatic lymphadenopathy (40%) or 
splenomegaly (26%), with many patients having more than one indication for treatment 
including disease symptoms such as fatigue or night sweats (Table 1). Although 32% of 
patients had substantial fatigue when entering study, only 5% were started on CLL 
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treatment solely for fatigue that was considered to have interfered with work or usual 
activities. With a median follow-up for this extended analysis of 29 months (maximum, 
36 months), 107 patients (79%) remain on first-line ibrutinib. 
 
Survival outcomes 
Ibrutinib resulted in significantly longer PFS compared with chlorambucil (median, PFS 
not reached vs 15.0 months; Figure 1A). There was an 88% reduction in risk of PFS 
events (progression or death; hazard ratio [HR], 0.12; 95% CI, 0.07-0.20; P < .0001) for 
patients randomized to ibrutinib. PFS at 24 months was 89% with ibrutinib versus 34% 
with chlorambucil. This rate was relatively stable with ibrutinib with an 18-month PFS of 
94%. Ibrutinib consistently demonstrated significant improvements in PFS for patients in 
all subgroups including those considered high risk (Figure 2). In patients treated with 
ibrutinib, only 1 patient with del(11q) has had disease progression and the rates of 24-
month PFS were 97% and 86% for those with or without del(11q), respectively (Figure 
1B). No significant difference was observed in the PFS of patients with unmutated 
versus mutated IGHV (24-month PFS, 90% and 89%, respectively; Figure 1C). PFS 
benefits were consistent across additional subgroups of patients, including those with 
advanced disease (Rai stage 3 or 4) or bulky disease (Figure 2). PFS and OS rates 
were also similar regardless of age (24-month PFS, <75 years [88%], ≥75 years [89%]; 
OS, <75 years [94%], ≥75 years [96%]; Figure S2). With longer follow-up and despite 
patient crossover, ibrutinib continues to demonstrate an OS benefit compared with 
chlorambucil (HR, 0.43; 95% CI, 0.21-0.86; P=.0145; Figure S3 and Table S1), with a 
24-month OS of 95% for ibrutinib vs. 84% for chlorambucil (Figure S3).  
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Responses for ibrutinib-treated patients 
With a maximum of 36 months of follow-up, the ORR with ibrutinib treatment was 92% 
(Table 2). Eighteen percent of patients achieved CR, which improved from 7% at 12 
months and 15% at 24 months (Figure 3). Comparable ORR and CR rates were also 
observed in high-risk subgroups, including those with del(11q) (ORR, 100%; CR rate, 
14%) or unmutated IGHV (ORR, 95%; CR rate, 21%).  
 
Disease burden and symptoms 
The vast majority of ibrutinib-treated patients experienced substantial reduction in 
lymphadenopathy and splenomegaly at the time of the primary analysis which was 
much greater than observed with chlorambucil. A ≥50% reduction in the lymph node 
sum of the product of longest diameter (SPD) occurred in 95% of patients treated with 
ibrutinib versus 40% of those treated with chlorambucil, with complete resolution in 
lymphadenopathy in 42% versus 7%, respectively (Figure S4A, B). Reduction in 
splenomegaly by ≥50% occurred in 95% with ibrutinib versus 52% with chlorambucil, 
with complete resolution in splenomegaly in 56% versus 22%, respectively (Figure S4C, 
D). Ibrutinib also resulted in higher rates of improvements in disease symptoms 
including weight loss, fatigue, and night sweats, which were indications for therapy in 
many patients. 
 
Patient-reported QOL 
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Greater improvements in QOL occurred with ibrutinib versus chlorambucil in FACIT-
Fatigue (P=.0013) by repeated measure analyses (Figure S5). Clinically meaningful 
improvements occurred more frequently with ibrutinib versus chlorambucil in FACIT-
Fatigue, although this was not statistically significant (86/136 [63%] vs 71/133 [53%]; 
odds ratio, 1.50; 95% CI, 0.92-2.45; P=.1013). 
 
Safety and tolerability of ibrutinib 
Median treatment duration with ibrutinib was 28.5 months (range, 0.7-35.9 months). 
Most patients continue ibrutinib treatment, with 83% (112/135) receiving ibrutinib 
continuously for durations exceeding 2 years. The most frequent AEs with ibrutinib with 
extended follow-up were similar to the primary report13: diarrhea, fatigue, cough, anemia, 
and nausea (Table S2). Grade ≥3 AEs were generally observed more frequently during 
the first 12 months of ibrutinib therapy and generally decreased over time (Figure 4). 
Rates of grade ≥3 cytopenias decreased over time from 8.1%, 5.9%, and 2.2% during 
the first year of treatment to 0%, 1%, and 0% during the third year of treatment for 
neutropenia, anemia, and thrombocytopenia, respectively. 
 
Several AEs of clinical interest were characterized in greater detail (Table 3). Diarrhea 
generally occurred early in treatment (median, 26 days) and was completely reversible 
in 95% of patients within a median of 6 days. Visual disturbances (blurred vision or 
reduced visual acuity) were grade 1 or 2, with 57% of these completely resolving within 
a median of 37.5 days after onset. Hypertension occurred at a median of 187 days, with 
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improvements reported at a median of 14 days after onset. Arthralgia was observed at a 
median of 135 days and was generally reversible (78% complete, 4% partial) within a 
median duration of approximately 3 weeks. Atrial fibrillation was observed throughout 
treatment follow-up, with 4% of patients experiencing a grade 3 event. Symptoms of 
atrial fibrillation quickly resolved in the majority of patients (57% complete, 7% partial 
resolution) within a median of 3 days. Nine patients (7%) experienced a major 
hemorrhage occurring at a median of 310 days. Of these, 3 patients were reported to 
have active treatment with concomitant medications that impact platelets or coagulation 
(aspirin, low molecular weight heparin, and naproxen respectively) including a traumatic 
hematoma, post-procedural hematoma, and hematuria, all of which were grade 3 in 
severity and did not result in study drug discontinuation. Grade ≥3 infection occurred in 
23% of patients at a median of 138 days, including 2 that were fatal (Klebsiella infection 
and septic shock). Grade ≥3 infections were observed most frequently in the first year of 
treatment and decreased thereafter (Figure 4). There were no cases of pneumocystis 
pneumonia or multifocal leukoencephalopathy reported.  
 
Serious AEs over the 3 years of follow-up occurring in more than 2 ibrutinib-treated 
patients, included pneumonia (11; 8%), atrial fibrillation (6; 4%), urinary tract infection (5; 
4%), basal cell carcinoma (5; 4%), hyponatremia (5; 4%), pleural effusion (4; 3%), 
hypertension (3; 2%), and anemia (3; 2%). 
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Eighteen patients (13%) required dose reductions and 16 patients (12%) discontinued 
first-line ibrutinib because of AEs. AEs leading to discontinuation in more than 1 patient 
included infection (n=5), hemorrhage (n=3), atrial fibrillation (n=2), and rash (n=2). 
Treatment-limiting toxicity including both reductions and discontinuations due to AEs 
decreased over time with ibrutinib (Figure 4). 
 
Concomitant medications 
Concomitant medications were collected throughout the duration of ibrutinib treatment 
(median, 28.5 months) and chlorambucil (median, 7.1 months). Despite longer follow-up 
recording of the use of these agents in the ibrutinib arm versus the chlorambucil arm, 
the rate of neutrophil growth factor use and platelet and red blood cell transfusion was 
higher in the chlorambucil arm. Intravenous immunoglobulin was administered to 4% of 
ibrutinib-treated patients versus 2% of those randomized to chlorambucil. 
Anticoagulants and/or antiplatelet agents were frequently used during study therapy (56% 
and 54% of patients treated with ibrutinib and chlorambucil, respectively; Table S3), 
including anticoagulants in 21% of the ibrutinib-treated patients.  
 
Outcomes following ibrutinib discontinuation 
With up to 3 years follow-up, out of 136 patients, only 4 patients discontinued ibrutinib 
primarily due to disease progression; 1 had unmutated IGHV and none were reported to 
have del(11q). Two of these 4 patients remain alive. Of the 16 patients who 
discontinued ibrutinib because of AEs; 13 (81%) are alive with a median of 13 months 
follow-up after ibrutinib discontinuation and 3 have died (Table S4). Ten of the patients 
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had PR as best response, 4 patients discontinued after not responding to ibrutinib and 2 
patients discontinued prior to response evaluation. Non-responders/non-evaluable had 
a PFS that ranged from 1.8 to 20.2 months, while responders tended to have a variable 
but longer PFS (4.2–34.0 months). As the vast majority of patients (79%) remain on 
single-agent ibrutinib, this analysis is limited in size and also to the patients who came 
off treatment fairly early (9 of the 16 patients who discontinued due to AEs did so in the 
first year). In total 7 patients received subsequent therapy after ibrutinib at a median of 
7.6 months following ibrutinib discontinuation (range, 1.2 to 20.8 months), including 
fludarabine-cyclophosphamide-rituximab (n=3), bendamustine-rituximab (n=2), 
chlorambucil (n=1), and radiation (n=1). Six of these 7 patients (86%) remain alive with 
median follow-up of 21 months (range, 9 to 25 months).  
 
Discussion 
This extended analysis of RESONATE-2 with detailed clinical follow-up demonstrates 
that ibrutinib continues to provide significant and sustained clinical benefits, improving 
the quality of responses, for the first-line treatment of older patients with CLL or SLL 
with a manageable safety profile over extended durations of treatment. Consistent with 
the initial report, ibrutinib demonstrates a significant 88% reduction in the risk of PFS 
events (progression or death) compared with chlorambucil (P < .0001) with extended 
follow-up. In addition, the OS benefit for ibrutinib compared with chlorambucil was 
maintained, despite crossover to treatment with ibrutinib for many patients in the 
chlorambucil arm (n=55). These data support the use of ibrutinib in the first-line 
treatment of CLL as a chemotherapy-free option that can be taken continuously 
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achieving long term disease control for the majority of patients including those with high 
risk features.10,13 Ibrutinib has a category 1 National Comprehensive Cancer Network® 
(NCCN®) recommendation as a single-agent first-line treatment for CLL without del(17p) 
in patients ≥65 years and for relapsed/refractory CLL without del(17p).18 
 
The efficacy of ibrutinib in the first-line setting appears superior to that observed in 
relapsed or refractory patients.19 Nearly all patients randomly assigned to ibrutinib 
achieved rapid disease reduction, with an ORR of 92% translating to high rates of 24-
month PFS and OS of 89% and 95%, respectively, with similar PFS and OS rates seen 
regardless of age. This observation suggests that ibrutinib may be most effective when 
used upfront before the acquisition of poor-risk molecular aberrations, which are 
selected for with chemotherapy.20,21 Additionally, sensitivity analyses to adjust for the 
effects of patients in RESONATE-2 who crossed over to ibrutinib found that treatment 
with ibrutinib was still associated with statically significant OS compared with 
chlorambucil.17 These results also demonstrate that depth of response substantially 
increases over time, with higher rates of CR during the extended follow-up, indicating a 
persistent action of the drug rather than a simple maintenance effect. Similar findings 
were observed with long-term follow-up of patients enrolled in the phase 2 trial of first-
line ibrutinib.11 Within this previous study, 29% of patients achieved a CR, and 92% 
remained alive and progression free at 5 years.22 Given this data, the CR rate will likely 
continue to increase in the present study as long-term disease control and high 
tolerability with first-line use can be expected based on the earlier phase 2 results.12  
 
 17 
 
In addition to the efficacy benefits overall, sustained robust outcomes were 
demonstrated in higher-risk groups. No difference in outcome was observed in patients 
with unmutated IGHV status, a traditional poor prognostic indicator for all 
chemoimmunotherapy regimens. Notably the rate of unmutated IGHV in this study of 
older patients was somewhat lower than other studies at 48% (vs. 58%-62% in CLL11), 
consistent with prior reports of higher frequency of unmutated IGHV in younger 
patients.4,23 For patients with del(11q), another traditionally high-risk subgroup, 100% of 
the 29 patients responded to treatment with ibrutinib, and there was a 99% reduction in 
the risk of progression or death, with only 1 del(11q) ibrutinib-treated patient 
experiencing disease progression after discontinuing therapy for AE over the extended 
follow-up. While this represents a relatively small patient subset (22%), ibrutinib 
demonstrates a particularly significant benefit in this population, which historically 
experiences inferior outcomes with traditional chemotherapy or CD20-based 
regimens.24-26 Combined analysis of 3 randomized studies not only demonstrated 
superiority of ibrutinib over traditional chemotherapy and/or anti-CD20 comparators for 
patients with del(11q), but also equally positive PFS and OS outcomes irrespective of 
del(11q). These results suggest that current definitions of high-risk disease and the 
impact of prognostic biomarkers may need to be redefined with ibrutinib.27 The 
mechanism why del(11q) patients may have better outcomes when treated with ibrutinib 
is of high interest and is the subject of ongoing research. 
 
Safety of therapy administered to older patients over the long term is an area that 
requires close scrutiny. First-line ibrutinib appears to be well tolerated with extended 
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treatment as evidenced by over 80% of this older population being able to continue 
treatment for more than 2 years. This extended follow-up allowed for new observations 
into the timing of when AEs occurred and time to resolution of AEs as well as the use of 
transfusions and growth factors. Diarrhea, while frequent, often occurred early during 
the first several months of treatment and was generally low grade and short lived. 
Severe and treatment-limiting AE rates decreased over time with extended ibrutinib 
treatment. A decrease in myelotoxicity and infectious complications over time was also 
observed. This contrasts with chemoimmunotherapy-associated AEs and was 
importantly associated with less medical resource utilization of neutrophil growth factors 
and slightly less transfusion need despite 4 times the treatment time with ibrutinib. While 
the rate of atrial fibrillation increased from 6% in the primary analysis13 to 10%, overall, 
ibrutinib dose reduction or discontinuation due to atrial fibrillation was uncommon and 
lessened with extended treatment in this population of older patients with CLL. Atrial 
fibrillation therefore appears manageable and does not frequently necessitate ibrutinib 
discontinuation.  Additional information on the management and outcomes of atrial 
fibrillation along with associated anticoagulant therapy has been provided in a large 
pooled analysis of ibrutinib studies.28 Rates of major hemorrhage remained low despite 
half the patients receiving concomitant antiplatelet or anticoagulant medications.  
 
Previous work demonstrated that QOL is significantly compromised in patients with CLL, 
affecting physical fitness, cognitive function, levels of fatigue, and sleep. Worse scores 
were reported for patients receiving chemotherapy such as chlorambucil.29 Even with 
the addition of contemporary anti-CD20 agents (obinutuzumab), no significant benefit in 
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QOL has been noted.4 However, this extended follow-up provides the first analysis of 
QOL, as measured by FACIT Fatigue Scale, following ibrutinib treatment in previously 
untreated patients. Significantly greater improvements in QOL were observed with 
ibrutinib versus chlorambucil. In line with this and the favorable impact on QOL and 
tolerable safety profile, 79% of patients remained on first-line treatment with ibrutinib at 
the time of this later analysis with up to 3 years of therapy. 
 
Patients who discontinue treatment for CLL including ibrutinib may have varied 
outcomes dependent on the reason for discontinuation.30 In 1 study that included mostly 
patients with relapsed or refractory CLL, median OS following ibrutinib therapy was 33 
months for those who discontinued because of AEs versus 16 months for those who 
discontinued because of disease progression. In our study, the 22 patients who 
discontinued therapy had a median follow-up of 13 months after discontinuation. Of 
these 22 patients, 16 are still alive, while 2 of the 4 patients who progressed have died. 
Seven patients have received subsequent treatment, mostly chemoimmunotherapy (BR, 
FCR); 6 of those patients are still alive with a median of 21 months of follow-up. While 
retrospective analyses of real-world data have previously suggested that treatment with 
an alternate kinase inhibitor is more effective than chemoimmunotherapy following 
discontinuation of ibrutinib,31,32 our data suggests that patients who discontinue ibrutinib 
can respond to chemoimmunotherapy as second line therapy. Continued follow-up of 
patients in the RESONATE-2 trial who have discontinued ibrutinib will provide the 
needed further data as relatively few patients have progressed or stopped therapy to 
date.   
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These data confirm that first-line treatment with ibrutinib results in long-term PFS in 
patients with CLL and that response quality continues to improve with ibrutinib over time 
with substantial increased in patients achieving CR. In addition, rates of grade ≥3 AEs 
during treatment with ibrutinib decreased over time. The most common reasons for 
initiating first-line treatment in these patients, including marrow failure, disease burden, 
and disease symptoms, all improved to greater extents in patients treated with ibrutinib 
versus chemotherapy. Ongoing randomized studies, including ILLUMINATE 
(NCT02264574), comparing ibrutinib-obinutuzumab with chlorambucil-obinutuzumab, 
and A041202 (NCT01886872), comparing ibrutinib, ibrutinib-rituximab, and rituximab-
bendamustine, will continue to define the role of ibrutinib for the first-line treatment of 
patients with CLL/SLL. 
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Tables 
Table 1. RESONATE-2 Reasons for Initiation of Treatment and Baseline Patient Characteristics1 
 
Ibrutinib 
(n=136) 
Chlorambucil 
(n=133) 
Baseline Characteristic   
Median age (range), y 
≥ 75 y, (%) 
73 (65-89) 
46 (34) 
72 (65-90) 
47 (35) 
Male, n (%) 88 (65) 81 (61) 
ECOG performance status, n (%) 
0 
1 
    2 
 
60 (44) 
65 (48) 
11 (8) 
 
54 (41) 
67 (50) 
12 (9) 
Rai stage III or IV, n (%) 60 (44) 62 (47) 
Bulky disease ≥ 5 cm, n (%) 54 (40) 40 (30) 
Hierarchical Classificationa, n (%)   
    Del(11q) 29/130 (22) 25/121 (21) 
    Trisomy 12 20/117 (17) 23/108 (21) 
    Del(13q) 25/112 (22) 32/108 (30) 
    None of above 38/112 (34) 28/108 (26) 
IGHV statusb, n/N (%)   
    Mutated 40/121 (33) 42/127 (33) 
    Unmutated 58/121 (48) 60/127 (47) 
Unclassifiablec 23/121 (19) 25/127 (20) 
Patients meeting criteria for active disease, n (%)   
Progressive marrow failure 54 (40) 49 (37) 
Lymphadenopathy 55 (40) 44 (33) 
Splenomegaly 36 (26) 44 (33) 
Progressive lymphocytosis 23 (17) 28 (21) 
Autoimmune anemia and/or thrombocytopenia 3 (2) 5 (4) 
Any documented constitutional symptoms 
Unintentional weight loss (>10% within 6 months) 
Significant fatigue 
Fever 
    Night sweats 
64 (47) 
14 (10) 
44 (32) 
4 (3) 
32 (24) 
56 (42) 
16 (12) 
29 (22) 
3 (2) 
35 (26) 
ECOG, Eastern Cooperative Oncology Group. FISH denotes fluorescence in situ hybridization, and 
IGHV the immunoglobulin heavy-chain variable-region gene 
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aPatients with missing results were excluded (Del(11): n=6 for ibrutinib, n=12 for chlorambucil; Trisomy 12: n=19 for ibrutinib, n=25 for 
chlorambucil; Del(13q): n=24 for ibrutinib, n=25 for chlorambucil; None of the above: n=24 for ibrutinib, n=25 for chlorambucil). 
bPatients with missing results were excluded (n=15 for ibrutinib, n=6 for chlorambucil). 
cUnclassifiable includes patients with polyclonal IGHV status if no specific IGHV subfamily member was dominant (>50% of all reads) and samples 
with no amplification. 
 
Table 2. Response rates in ibrutinib-treated patients  
Best 
response, n 
(%) 
Ibrutinib-treated patients 
All patients 
(n=136) 
With 
del(11q) 
(n=29) 
Without 
del(11q) 
(n=101) 
Mutated 
IGHV 
(n=40) 
Unmutated IGHV 
(n=58) 
ORR 125 (92) 29 (100) 91 (90) 35 (88) 55 (95) 
CR/CRi 25 (18) 4 (14) 20 (20) 8 (20) 12 (21) 
nPR  1 (1) 0 1 (1) 3 (8) 0 
PR 97 (71) 25 (86) 68 (67) 26 (65) 43 (74) 
PR-L 2 (1) 0 2 (2) 0 0 
CRi, complete response with incomplete blood-count recovery; nPR, nodular partial response (defined according to the International Workshop on Chronic 
Lymphocytic Leukemia criteria for response16 as a complete response with lymphoid nodules in the bone marrow); PR, partial response; PR-L, partial 
response with lymphocytosis. 
 
 
 
Table 3. Characterization of select AEs of clinical interest in ibrutinib-treated patients observed at any time during follow-upa 
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AE 
Ibrutinib-treated patients  
n=135 
n (%) 
Resolution,  
n (%) 
Median time to first event,  
days 
Median time from onset to 
resolution/ improvement, 
days 
Grade Any 2 3 4 5 Complete Partial Any 2 3 4 5 Any 2 3 4 
Diarrhea 61 (45) 
16 
(12) 5 (4) 0 0 58 (95) 0 26 131 219 NA NA 6 3 6.5 NA 
Visual 
disturbancesb 
30 
(22) 6 (4) 0 0 0 17 (57) 0 100 201 NA NA NA 37.5 74.5 NA NA 
Hypertensionc 27 (20) 
13 
(10) 7 (5) 0 0 12 (44) 1 (4) 187 187 109.5 NA NA 14 36 9 NA 
Arthralgia 27 (20) 9 (7) 3 (2) 0 0 21 (78) 1 (4) 135 55 135 NA NA 22 22 15 NA 
Atrial 
fibrillation 
14 
(10) 7 (5) 6 (4) 0 0 8 (57) 1 (7) 249.5 85 773.5 NA NA 3 2 7 NA 
Major 
hemorrhage 9 (7) 
1  
(< 1) 7 (5)
 1 (1) 0 9 (100) 0 310 155 446 254 NA 13.5 14.0 11.0 45.0 
Infections 
(grade ≥3) 
31 
(23) NA 
28 
(21) 4 (3) 2 (1) 28 (90) 0 138 NA 119
 367.5 422 9 NA 9 16 
AE, adverse event; NA, not applicable. 
aFrom first dose of study treatment up to 30 days after last dose or initiation of subsequent anti-cancer therapy, whichever occurs earlier  
bVisual disturbances included the preferred terms blurred vision and reduced visual acuity 
cHypertension (standardized MEDRA queries) group of preferred terms. 
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Figure Legends 
Figure 1. PFS for the intent-to-treat population. Survival analyses from randomization 
until event or censored at last follow-up using the Kaplan-Meier method. Vertical ticks 
indicate censored patients. 
PFS, progression-free survival. 
 
Figure 2. PFS subgroup analysis.  
 
Figure 3. Response rates over time in ibrutinib-treated patients. 
CR, complete response; CRi, complete response with incomplete blood-count recovery; 
nPR, nodular partial response (defined according to the International Workshop on 
Chronic Lymphocytic Leukemia criteria for response16 as a complete response with 
lymphoid nodules in the bone marrow); PR, partial response; PR-L, partial response 
with lymphocytosis. 
 
Figure 4. Safety and tolerability of ibrutinib over time. Rate of grade ≥3 AEs, 
discontinuations due to AEs, and dose reductions over different periods of time.  AE, 
adverse events 
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1. Figure S1. Patient flow with extended follow-up in the RESONATE-2 trial 
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A
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4. Table S1. OS adjusted for crossover 
Method 
Cox model Log-rank P value 
HR 95% CI 
ITT 0.43 0.21-0.86 .0145 
RPSFT modela 0.28 0.13-0.60 — 
Excluding crossover patientsb 0.31 0.15-0.66 .0013 
CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; ITT, intention-to-
treat; OS, overall survival; RPSFT, rank-preserving structural failure time. 
a Cox model including treatment and baseline covariates to compensate for any lack of balance between treatment arms and 
improve precision (ECOG PS, Rai stage, age, sex, bulky disease, del11q, region, ethnicity, lactate dehydrogenase, β2-
microglobulin, creatinine clearance).  
b Analysis stratified by 2 randomization factors: ECOG PS (0/1 vs 2) and Rai stage (0/I/II vs III/IV) at baseline as reported in the 
interactive web response system. 
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5. Figure S4. Reductions in lymphadenopathy and splenomegaly over time with 
ibrutinib treatment. 
 
  
CRi, complete response with incomplete blood-count recovery; NPR, nodular partial response; PD, progressive disease; PR, partial 
response; PR-L, partial response with lymphocytosis; SD, stable disease; SPD, sum of the product of perpendicular diameters of 
lymph nodes; UNK/NE, unknown/not evaluable. 
Of patients with baseline lymphadenopathy, 95% (124/130) experienced a  50% reduction in the lymph node sum of the product of 
longest diameter (SPD) with ibrutinib versus 40% (49/123) of those treated with chlorambucil, with complete resolution in 42% 
(55/130) versus 7% (9/123), respectively (A and B). Of those with baseline splenomegaly, 95% (103/108) experienced a ≥ 50% 
reduction with ibrutinib versus 52% (52/100) with chlorambucil, with complete resolution in splenomegaly in 56% (60/108) versus 
22% (22/100), respectively (C and D). 
a For patients with measurable disease at baseline, reductions in lymphadenopathy and spleen size were measured by an 
Independent Review Committee at the time of primary analysis while best response was investigator assessed.  
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7. Table S2. Most frequent AEs (≥15%) in ibrutinib-treated patients 
AEs, n (%) 
Ibrutinib-treated patients 
(n=135) 
Median duration of treatment = 28.5 months (range, 0.7-35.9 months) 
Any grade Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Diarrhea 61 (45) 40 (30) 16 (12) 5 (4) 0 0 
Fatigue 44 (33) 29 (21) 13 (10) 2 (1) 0 0 
Cough 38 (28) 30 (22) 8 (6) 0 0 0 
Anemia 31 (23) 8 (6) 14 (10) 8 (6) 1 (1) 0 
Nausea 31 (23) 21 (16) 9 (7) 1 (1) 0 0 
Peripheral edema 29 (21) 20 (15) 7 (5) 2 (1) 0 0 
Arthralgia 27 (20) 15 (11) 9 (7) 3 (2) 0 0 
Pyrexia 27 (20) 17 (13) 9 (7) 0 0 1 (1) 
URTI 26 (19) 7 (5) 16 (12) 3 (2) 0 0 
Dry eye 25 (19) 23 (17) 2 (1) 0 0 0 
Hypertension 24 (18) 4 (3) 13 (10) 7 (5) 0 0 
Neutropenia 23 (17) 3 (2) 4 (3) 8 (6) 8 (6) 0 
Vomiting 23 (17) 15 (11) 8 (6) 0 0 0 
Constipation 22 (16) 16 (12) 5 (4) 1 (1) 0 0 
Blurred vision 22 (16) 17 (13) 5 (4) 0 0 0 
AE, treatment-emergent adverse event; URTI, upper respiratory tract infection. 
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8. Frequent concomitant medications of clinical interest 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Types of concomitant 
medications, n (%) 
Ibrutinib 
(n=135) 
median DOT = 28.5 months 
(range, 0.7-35.9 months) 
Chlorambucil 
(n=132) 
median DOT = 7.1 months (range, 
0.5-11.7 months) 
Antiplatelet agents 
Acetylsalicylic acid (aspirin) 
NSAIDs 
Clopidogrel 
66 (49) 
45 (33) 
35 (26) 
8 (6) 
67 (51) 
48 (36) 
23 (17) 
4 (3) 
Anticoagulants 
LMWH 
Heparin 
Direct oral anticoagulants 
28 (21) 
19 (14) 
5 (4) 
6 (4) 
13 (9) 
6 (5) 
1 (1) 
6 (5) 
Neutrophil growth factors 12 (9) 16 (12) 
RBC transfusions 20 (15) 21 (16) 
Platelet transfusions 2 (1) 3 (2) 
Intravenous immunoglobulin 6 (4) 2 (2) 
DOT, duration of treatment; LMWH, low-molecular-weight heparin; NSAID, nonsteroidal anti-inflammatory drug; RBC, red blood cell. 
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9. Table S4. Patients who discontinued ibrutinib due to AEs and died 
Patient AE leading to discontinuation 
OS, 
months 
Last dose of 
ibrutinib to death, 
days 
1 
Bilateral pneumonia 
(Legionella 
pneumophylae) 
3.5 39 
2 
Secondary 
malignancy (non-
small cell lung 
cancer) 
20.2 180 
3 Fever 21.5 5 
 
AE, adverse event; OS, overall survival. 
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